Duchenne Muscular Dystrophy – Pipeline Review, H2 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/393093 .
Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 12, 11, 2, 53 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 1 molecules, respectively.
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in…